Activation of the PI3K-AKT pathway in human malignant mesothelioma cells

Molecular Medicine Reports

Volumn 2, Issue 2, 2009, Pages 181-188

  Suzuki, Yutaro ^a,b   Murakami, Hideki ^a   Kawaguchi, Koji ^a,b   Taniguchi, Tetsuo ^a,b   Fujii, Makiko ^a   Shinjo, Keiko ^a   Kondo, Yutaka ^a   Osada, Hirotaka ^a   Shimokata, Kaoru ^c   Horio, Yoshitsugu ^a   Hasegawa, Yoshinori ^b   Hida, Toyoaki ^a   Sekido, Yoshitaka ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CHUBU UNIVERSITY   (Japan)

Author keywords

AKT; Malignant mesothelioma; Phosphatidylinositol 3 kinase; PTEN

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE LKB1;

ARTICLE; CANCER CELL CULTURE; CELL IMMORTALIZATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; EXON; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 67650099861     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000081     Document Type: Article

References (43)

1. Pass HI, Vogelzang N, Hahn S and Carbone M: Malignant pleural mesothelioma. Curr Probl Cancer 28: 93-174, 2004.
2. Peto J, Decarli A, La Vecchia C, Levi F and Negri E: The European mesothelioma epidemic. Br J Cancer 79: 666-672, 1999.
3. Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603, 2005.
4. Murayama T, Takahashi K, Natori Y and Kurumatani N: Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med 49: 1-7, 2006. (Pubitemid 43083291)
5. Van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C and Giaccone G: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer, Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889, 2005. (Pubitemid 46260274)
6. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C and Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003. (Pubitemid 46606305)
7. Murthy SS and Testa JR: Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 180: 150-157, 1999.
8. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM and Testa JR: Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 53: 4349-4355, 1993. (Pubitemid 24146789)
9. Balsara BR, Bell DW, Sonoda G, De Rienzo A, Du Manoir S, Jhanwar SC and Testa JR: Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 59: 450-454, 1999. (Pubitemid 29048882)
10. Krismann M, Muller KM, Jaworska M and Johnen G: Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases. J Pathol 197: 363-371, 2002. (Pubitemid 34778307)
11. Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K, Ueda Y, Mitsudomi T, Horio Y, Hida T, Yatabe Y, Seto M and Sekido Y: Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 98: 438-446, 2007. (Pubitemid 46195618)
12. Bell DW, Jhanwar SC and Testa JR: Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res 57: 4057-4062, 1997.
13. Lee WC, Balsara B, Liu Z, Jhanwar SC and Testa JR: Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. Cancer Res 56: 4297-4301, 1996. (Pubitemid 26330424)
14. Bjorkqvist AM, Tammilehto L, Anttila S, Mattson K and Knuutila S: Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 75: 523-527, 1997. (Pubitemid 27085293)
15. Kratzke RA, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J and Kaye FJ: Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 87: 1870-1875, 1995.
16. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ and Testa JR: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54: 5547-5551, 1994. (Pubitemid 2158337)
17. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM and Fletcher JA: Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11: 511-515, 1995.
18. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, Kley N, Klein-Szanto AJ and Testa JR: High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 92: 10854-10858, 1995.
19. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF and Minna JD: Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55: 1227-1231, 1995.
20. Carbone M, Kratzke RA and Testa JR: The pathogenesis of mesothelioma. Semin Oncol 29: 2-17, 2002.
21. Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274, 2007.
22. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B and Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554, 2004. (Pubitemid 38541907)
23. Eng C: PTEN: one gene, many syndromes. Hum Mutat 22: 183-198, 2003.
24. Mehenni H, Lin-Marq N, Buchet-Poyau K, Reymond A, Collart MA, Picard D and Antonarakis SE: LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes. Hum Mol Genet 14: 2209-2219, 2005. (Pubitemid 41418020)
25. Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB and Testa JR: Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24: 6080-6089, 2005. (Pubitemid 43080058)
26. Papp T, Schipper H, Pemsel H, Unverricht M, Muller KM, Wiethege T, Schiffmann D and Rahman Q: Mutational analysis of the PTEN/MMAC1 tumour suppressor gene in primary human malignant mesotheliomas. Oncol Rep 8: 1375-1379, 2001. (Pubitemid 33758751)
27. Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, Yokoi K, Horio Y, Shimokata K, Sekido Y and Hida T: Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 97: 387-394, 2006.
28. Hartmann W, Digon-Sontgerath B, Koch A, Waha A, Endl E, Dani I, Denkhaus D, Goodyer CG, Sorensen N, Wiestler OD and Pietsch T: Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 12: 3019-3027, 2006. (Pubitemid 43837346)
29. Enomoto A, Murakami H, Asai N, Morone N, Watanabe T, Kawai K, Murakumo Y, Usukura J, Kaibuchi K and Takahashi M: Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev Cell 9: 389-402, 2005. (Pubitemid 41235808)
30. Hlobilkova A, Guldberg P, Thullberg M, Zeuthen J, Lukas J and Bartek J: Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity. Exp Cell Res 256: 571-577, 2000. (Pubitemid 30244215)
31. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA and Borden EC: Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 25: 2406-2413, 2007. (Pubitemid 46999211)
32. Kawaguchi K, Oda Y, Saito T, Takahira T, Yamamoto H, Tamiya S, Iwamoto Y and Tsuneyoshi M: Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas. Hum Pathol 36: 357-363, 2005. (Pubitemid 40591805)
33. Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH and Bose S: PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 112: 407-410, 2004. (Pubitemid 39390604)
34. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK and Kelsey KT: PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 36: 768-776, 2005. (Pubitemid 41112032)
35. Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, Moch H and Weder W: PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 33: 502-506, 2008.
36. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP and Yin Y: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128: 157-170, 2007. (Pubitemid 46048887)
37. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL and Salgia R: Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66: 352-361, 2006. (Pubitemid 43166042)
38. Ramos-Nino ME, Blumen SR, Sabo-Attwood T, Pass H, Carbone M, Testa JR, Altomare DA and Mossman BT: HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol 38: 209-217, 2008. (Pubitemid 351162843)
39. Janne PA, Taffaro ML, Salgia R and Johnson BE: Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 62: 5242-5247, 2002. (Pubitemid 35024597)
40. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, Rizzi A, Bosari S and Roncalli M: EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinicopathological correlations. Lung Cancer 51: 207-215, 2006.
41. Langerak AW, De Laat PA, van der Linden-van Beurden CA, Delahaye M, van der Kwast TH, Hoogsteden HC, Benner R and Versnel MA: Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 178: 151-160, 1996. (Pubitemid 26057966)
42. Rascoe PA, Cao X, Daniel JC, Miller SD and Smythe WR: Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma. J Thorac Cardiovasc Surg 130: 393-400, 2005. (Pubitemid 41074170)
43. Mohiuddin I, Cao X, Ozvaran MK, Zumstein L, Chada S and Smythe WR: Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of AKT phosphorylation. Ann Surg Oncol 9: 310-316, 2002. (Pubitemid 34298638)